Troy Wilson, Kura CEO
November 24, 2021 07:01 AM ESTUpdated 10:30 AM
R&D
FDA+

FDA hits the red light on an ear­ly-stage AML study af­ter a pa­tient dies

John Carroll

Editor & Founder

Max Gelman

Senior Editor

The FDA has slapped a clin­i­cal hold on the ear­ly-stage pro­gram for one of Ku­ra On­col­o­gy’s can­cer drugs fol­low­ing a pa­tient’s death in a clin­i­cal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times